Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma

Omar Al-Odat, Max von Suskil, Robert Chitren, Weam Elbezanti, Sandeep Srivastava, Tulin Budak-Alpddogan, Subash Jonnalagadda, Bharat Aggarwal, Manoj Pandey

Research output: Contribution to journalReview articlepeer-review

Abstract

Multiple myeloma (MM) is a plasma cells neoplasm. The overexpression of Bcl-2 family proteins, particularly myeloid cell leukemia 1 (Mcl-1), plays a critical role in the pathogenesis of MM. The overexpression of Mcl-1 is associated with drug resistance and overall poor prognosis of MM. Thus, inhibition of the Mcl-1 protein considered as a therapeutic strategy to kill the myeloma cells. Over the last decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement. This review presents the critical role of Mcl-1 in the progression of MM, the most prominent BH3 mimetic and semi-BH3 mimetic that selectively inhibit Mcl-1, and could be used as single agent or combined with existing therapies.

Original languageEnglish (US)
Article number699629
JournalFrontiers in Pharmacology
Volume12
DOIs
StatePublished - Jul 19 2021

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma'. Together they form a unique fingerprint.

Cite this